This study suggests that XXMD exerts neuroprotective effects by down-regulating the expression levels of LC3B, Beclin1, and Lamp1 proteins, thereby reducing mitochondrial activation and improving mitochondrial function in cerebral ischemia-reperfusion injury. This evidence concerns the gene MAP1LC3B and brain ischemia.